Atlas Trials

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Clinical trial NCT04526210 · COMPLETED

Trial details

NCT number
NCT04526210
Sponsor
Alexion Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Wilson Disease
Start date
2020-10-21
Primary completion
2021-05-28
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.